Status:
COMPLETED
Measuring Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA
Lead Sponsor:
Imperial College London
Conditions:
Cerebral Metastases
Eligibility:
All Genders
18+ years
Brief Summary
Cerebral metastases represent a significant problem for oncological management. It is estimated that 20-40% of patients with cancer will develop metastatic cancer to the brain during the course of the...
Detailed Description
24 evaluable patients with radiological evidence of cerebral metastases on MRI will be enrolled into the study (12 who are treatment naïve + 12 who have completed Stereotactic Radiosurgery (SRS)+/- co...
Eligibility Criteria
Inclusion
- A) Treatment naïve
- or
- B) SRS+/- combination treated - Patients that have completed the SRS part of a combination regime enabling a 4-8 week post-SRS treatment PET/MRI scan.
- and
- C) That fulfil the following criteria:
- Age ≥18.
- Target metastases size ≥ 1cm.
- WHO performance status 0 - 2.
- If female, the subject is either post-menopausal (at least 1 year), or surgically sterilized (has had a documented bilateral oophorectomy and/or documented hysterectomy for at least 2 years), or if of childbearing potential, must have a negative urine beta human chorionic gonadotropin (beta-hCG) pregnancy test done prior to tracer administration.
- The subject is able and willing to comply with study procedures, and signed and dated informed consent is obtained.
- The subject has a satisfactory medical history as judged by the investigator with no significant co-morbidities.
- The subject's clinical and laboratory tests are within normal limits and/or considered clinically insignificant.
Exclusion
- The subject is pregnant or lactating.
- Any other chronic illness that will or musculoskeletal condition that would not allow comfortable performance of a PET study.
- Prior use within 14 days of enrolment or concurrent therapy with any other investigational agent.
- Unsatisfactory renal function (eGFR\<30).
- The subject has non-MRI compatible devices (e.g.a pacemaker, an implantable cardioverter-defibrillator (ICD), a nerve stimulator, a cochlear implant or a drug pump) or implanted material (e.g. non-MRI compatible sternal wires, biostimulators, metals or alloys).
Key Trial Info
Start Date :
September 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT04807582
Start Date
September 25 2020
End Date
March 1 2024
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College Healthcare NHS Trust
London, United Kingdom, W12 0HS